Camden Town Hall Weighs Psychedelic Therapy Pilots

Residents voiced divided views on psychedelic-assisted therapy at a Camden Coalition forum ahead of New Jersey's planned research pilots.

Updated on Nov. 19, 2026 in Mental Health

Camden Town Hall Weighs Psychedelic Therapy Pilots

Live Poll

Should Medicaid cover psychedelic-assisted therapy once research confirms it works?

The Camden Coalition held a town hall in September 2026 in Camden, New Jersey, to educate residents on the state's psychedelic-assisted therapy research and gather community views. Residents were divided, with some supportive and others questioning the research and its efficacy.

Why it matters

New Jersey is setting up 3 state-funded research pilots for psychedelic-assisted therapy, and community input is being gathered before potential FDA approval of such treatments. Residents asked that any care model honor spirituality, culture, and lived experience.

New Jersey is establishing 3 state-funded research pilots for psychedelic-assisted therapy, and several psychedelic drugs are in phase 3 trials, some with breakthrough therapy designation. Specific pilot locations and start dates have not been identified.

The players

Camden Coalition

The Camden Coalition is a Camden, New Jersey health organization focused on improving care for residents, and it hosted the town hall and gathered community attitudes on psychedelic-assisted therapy.

Scattergood Foundation

The Scattergood Foundation is a philanthropic organization that supports community engagement work, and it is supporting the Camden Coalition's effort on psychedelic-assisted therapy.

The details

At the September 2026 town hall, residents asked for plain-language evidence on effectiveness, dosing, and risk, equitable access across Medicaid, Medicare, and commercial insurance, and community input in site selection and shared decision-making. Esketamine (Spravato), an FDA-approved treatment, is already offered by clinicians in New Jersey.

Timeline

  1. September 2026: Camden Coalition holds town hall on psychedelic-assisted therapy in Camden, New Jersey.

Big Picture

Several psychedelic drugs are in phase 3 trials with breakthrough therapy designation from the FDA, and New Jersey's state-funded pilots are being designed ahead of possible approval. The Camden effort places community input ahead of that regulatory milestone rather than after it.

Camden residents who want input on the pilots can attend future community sessions and ask how site selection and shared decision-making will work. Patients in New Jersey already have access to FDA-approved esketamine (Spravato) through local clinicians.

The takeaway

Community input is being sought before New Jersey's psychedelic therapy pilots take shape, so residents who want evidence on dosing, risk, and access can raise those questions now.

Further reading

Explore more on Mental Health coverage and treatment research.

Source note: This article includes information reported by Ajmc.

Live Poll

Should Medicaid cover psychedelic-assisted therapy once research confirms it works?